Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Head and Neck Regimens



Salivary gland Regimens


Published

Name Version Date
HN SAL Metastatic - CAP [CYCLOPHOSPHamide, DOXOrubicin and cISplatin]1.0.002/06/2022
HN SAL Metastatic - cISplatin and vinORELBine [IV]1.0.002/06/2022

Squamous cell Regimens


Published

Name Version Date
HN SQCC Metastatic - cARBOplatin and fluorouracil [Q3W]1.0.002/06/2022
HN SQCC Metastatic - cARBOplatin and PACLItaxel3.0.006/09/2023
HN SQCC Metastatic - cARBOplatin, fluorouracil and pembrolizumab1.0.002/06/2022
HN SQCC Metastatic - cISplatin and fluorouracil1.0.002/06/2022
HN SQCC Metastatic - cISplatin, fluorouracil and pembrolizumab1.0.002/06/2022
HN SQCC Metastatic - metHOTREXATe1.0.007/11/2022
HN SQCC Metastatic - nivolumab [weight-based dosing]1.0.005/05/2022
HN SQCC Metastatic - nivolumab Q2W [flat dosing]1.0.002/06/2022
HN SQCC Metastatic - nivolumab Q4W [flat dosing]1.0.005/05/2022
HN SQCC Metastatic - PACLItaxel Q1W1.0.002/06/2022
HN SQCC Metastatic - pembrolizumab Q3W [flat dosing]1.0.005/05/2022
HN SQCC Metastatic - pembrolizumab Q3W [weight-based dosing]1.0.002/06/2022
HN SQCC Metastatic - pembrolizumab Q6W [flat dosing]1.0.005/05/2022
HN SQCC NON-Metastatic - cARBOplatin and fluorouracil chemoradiation1.0.005/05/2022
HN SQCC NON-Metastatic - CETUximab chemoradiation1.0.007/11/2022
HN SQCC NON-Metastatic - cISplatin [Q1W] chemoradiation1.0.002/06/2022
HN SQCC NON-Metastatic - cISplatin [Q1W] post-operative chemoradiation2.0.006/09/2023
HN SQCC NON-Metastatic - cISplatin [Q3W] chemoradiation1.0.002/06/2022
HN SQCC NON-Metastatic - cISplatin [Q3W] post-operative chemoradiation1.0.002/06/2022
HN SQCC NON-Metastatic - TPF [DOCEtaxel, ciSplatin and fluorouracil] followed by cARBOplatin chemoradiation1.0.007/11/2022

Thyroid Regimens


Published

Name Version Date
HN THY Metastatic - leNVAtinib1.0.003/06/2022